Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PTAFR | P25105 | 2/20 | 0.45 |
| ▸ | OPRM1 | P35372 | 3/20 | 0.40 |
| ▸ | OPRD1 | P41143 | 3/20 | 0.40 |
| ▸ | OPRK1 | P41145 | 3/20 | 0.40 |
| ▸ | OPRL1 | P41146 | 3/20 | 0.40 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.40 |
| ▸ | RECQL | P46063 | 1/20 | 0.40 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.40 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.40 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.40 |
| ▸ | SLC6A9 | P48067 | 1/20 | 0.38 |
| ▸ | GAA | P10253 | 1/20 | 0.38 |
| ▸ | POLB | P06746 | 1/20 | 0.38 |
| ▸ | CACNA2D1 | P54289 | 1/20 | 0.37 |
| ▸ | CACNA1B | Q00975 | 1/20 | 0.37 |
| ▸ | CACNB1 | Q02641 | 1/20 | 0.37 |
| ▸ | CACNA1C | Q13936 | 1/20 | 0.37 |
| ▸ | MAOB | P27338 | 1/20 | 0.37 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL10046467 | 0.95 | ALDH1A1 (0.42) | PTAFROPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL10046459 | 0.89 | PTAFR (0.42) | PTAFROPRM1OPRD1OPRK1ALDH1A1 | |
| SCHEMBL522530 | 0.89 | CYP19A1 (0.41) | PTAFROPRM1OPRK1ALDH1A1RECQL | |
| SCHEMBL10046472 | 0.86 | OPRK1 (0.45) | OPRM1OPRD1OPRK1OPRL1ALDH1A1 | |
| SCHEMBL10046461 | 0.85 | OPRL1 (0.45) | PTAFROPRL1ALDH1A1RECQLCYP3A4 | |
| SCHEMBL10046462 | 0.85 | PTAFR (0.44) | PTAFROPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL522532 | 0.85 | SLC6A3 (0.44) | PTAFROPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL522257 | 0.84 | PTAFR (0.47) | PTAFROPRM1OPRD1OPRK1OPRL1 | |
| SCHEMBL10046463 | 0.82 | OPRD1 (0.50) | OPRM1OPRD1OPRK1OPRL1CYP3A4 | |
| SCHEMBL522607 | 0.81 | OPRK1 (0.43) | PTAFROPRM1OPRD1OPRK1OPRL1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2421836-A1 | 2-ARYL IMIDAZOLINE DERIVATIVES | MSD K.K. (JP) | 2012-02-29 | — | — | EP | claimed |
| US-20120029041-A1 | 2-ARYL IMIDAZOLINE DERIVATIVES | MSD K.K. (JP) | 2012-02-02 | — | — | US | claimed |
| WO-2010123150-A1 | 2-ARYL IMIDAZOLINE DERIVATIVES | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-10-28 | — | — | WO | claimed |
| EP-2421836-A1 | 2-ARYL IMIDAZOLINE DERIVATIVES | MSD K.K. (JP) | 2012-02-29 | — | — | EP | disclosed |
| US-20120029041-A1 | 2-ARYL IMIDAZOLINE DERIVATIVES | MSD K.K. (JP) | 2012-02-02 | — | — | US | disclosed |
| US-20120029041-A1 | 2-ARYL IMIDAZOLINE DERIVATIVES | MSD K.K. (JP) | 2012-02-02 | — | — | US | disclosed |
| US-20120029041-A1 | 2-ARYL IMIDAZOLINE DERIVATIVES | MSD K.K. (JP) | 2012-02-02 | — | — | US | disclosed |
| WO-2010123150-A1 | 2-ARYL IMIDAZOLINE DERIVATIVES | BANYU PHARMACEUTICAL CO.,LTD. (JP) | 2010-10-28 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120029041-A1 | 2-ARYL IMIDAZOLINE DERIVATIVES | CLIC1, NAT1, NMRAL1 | PTAFR 4849/4885OPRM1 677/4885OPRD1 828/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.